Sugammadex and its effect on respiratory outcome in obstructive sleep apnea patients undergoing laproscopic bariatric surgery

Abstract

Background Obesity has clearly emerged as a worldwide epidemic, and because obesity is a well-recognized risk factor for the development of obstructive sleep apnea (OSA), physicians will undoubtedly encounter patients with OSA undergoing surgery. The increased incidence of postoperative respiratory problems in patients with OSA could be explained by the depressive effects of narcotics as well as other anesthetic drugs on the function of the upper airway muscles. Anesthesia may also attenuate the ventilatory response to airway obstruction and abolish normal response to hypoxia and hypercapnia. Aim The aim of this work was to evaluate sugammadex and its effect on the respiratory outcome in OSA patients undergoing laparoscopic bariatric surgery. Patients and methods Patients were included in the study after obtaining informed written consent (IRB NO: 000007555-FWA NO: 00015712). Inclusion criteria were as follows: age between 18 and 55 years, obesity (BMI>40), known OSA case with mild-to-moderate apnea–hypopnea index ( Results The mean time for recovery to TOF of 0.9 was recorded from the time of administration of the drug. It was shorter in the sugammadex group than that in the neostigmine group. As regards the vital signs of both groups in the postoperative period, vitals were relatively stable in the sugammadex group, whereas there were significant tachypnea, hypoxia, and tachycardia in the other group. Respiratory distress signs were much more frequent in the neostigmine group than in the sugammadex group. This concludes that sugammadex may improve the postoperative respiratory outcome in OSA patients undergoing baraiatric surgery. Conclusion Sugammadex may improve the postoperative respiratory outcome in OSA patients undergoing baraiatric surgery.